| Authors: |
Davies JS; NCI, National Institutes of Health, Bethesda, Maryland, USA.; Safety Assessment, Genentech Inc, South San Francisco, California, USA., Karimipour F; NCI, National Institutes of Health, Bethesda, Maryland, USA., Zhang L; NCI, National Institutes of Health, Bethesda, Maryland, USA., Nagarsheth N; NCI, National Institutes of Health, Bethesda, Maryland, USA., Norberg S; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Serna C; NCI, National Institutes of Health, Bethesda, Maryland, USA.; Immuno-Oncology Translational Medicine, AstraZeneca Gaithersburg, Gaithersburg, Maryland, USA., Strauss J; Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA., Chiou S; Cancer Immunotherapy, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Gulley JL; NCI, National Institutes of Health, Bethesda, Maryland, USA., Hinrichs CS; Cancer Immunotherapy, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA ch977@cinj.rutgers.edu. |
